Reforming generic drug pricing in Canada

February 13th, 12:00noon ET

Watch the video

Synopsis:

 

Because generics offer the same quality advantages as their branded counterparts, generic drug manufacturers compete for market share by offering low prices. The Ontario Drug Benefit (ODB) program currently has a fixed rate which does not necessarily align with the cost of producing the drugs.  

 

This session of CHSRF on Call focuses on two options for generic drug pricing:

  • the implementation of sliding scale, and
  • using tendering systems

to reward producers while better aligning payment with production costs. Join the discussion.

 

Guest Speakers:

 

Aidan Hollis Aidan Hollis, Professor, Dept of Economics, University of Calgary

 

Aidan Hollis was educated at Cambridge University and the University of Toronto, where he obtained a PhD in Economics. His research is broadly in the area of industrial organization, and is particularly focused on competition and innovation issues in pharmaceutical markets.

He is Vice-President and a Director of Incentives for Global Health, a non-profit whose chief objective is the promotion and development of the Health Impact Fund.

Prof. Hollis has also published on electricity market restructuring, international aspects of competition policy, and the economics of a historical microcredit institution. For the academic year 2003-4 he was appointed TD MacDonald Chair of Industrial Economics at the Competition Bureau, Industry Canada.

 

 

 

Matthew Brougham Matthew Brougham, Vice-President, Products and Services, Canadian Agency for Drugs and Technology in Health

 

Having joined CADTH in September 2011, he is responsible for overseeing the research, development, and delivery of the Agency’s products and services that contribute to the optimal use of drugs and health technologies in Canada.

He is also responsible for collaborating with other organizations that conduct health technology assessments, in Canada and abroad.

 

As the former Chief Executive of PHARMAC in New Zealand, Matthew has significant expertise in maximizing the health benefits of pharmaceuticals through the use of objective economic assessment and prioritization processes to support evidence-based decision-making. 

 

Matthew’s professional experience covers a wide range of policy areas, including fisheries science, transportation, social welfare, health economics, and taxation. He maintains involvement in a number of organizations, including the International Network of Agencies for Health Technology Assessment (INAHTA) and Health Technology Assessment International (HTAi).

 

Matthew has an academic background in economics and science, which he studied at the University of Tromsø (Norway), and at Lincoln and Canterbury Universities (New Zealand).

 

Host:

 

Stephen SamisStephen Samis, Vice-President, Programs, CHSRF 

 

Stephen has more than 15 years experience in research, policy development, knowledge exchange, partnership development and advocacy in the health sector. Prior to CHSRF he was director of Health Policy at the Heart and Stroke Foundation of Canada from 2004 to 2010 and manager of Research and Analysis at the Canadian Institute for Health Information from 2000 to 2004. Before moving to Ottawa in 2000, Stephen was a health research and policy consultant in British Columbia, where he worked for the BC Ministry of Health, Health Canada, the BC Workers Compensation Board and others.

 

Stephen has a strong interest in health research and policy, population health and evidence-informed policy development to improve Canada's health systems and ultimately the health of Canadians. He holds a Master’s degree in Sociology from Simon Fraser University in British Columbia.